Skip to content

BJCP article: Analysis examines safety of antidepressant use during pregnancy

Use of fluoxetine – the most commonly prescribed antidepressant – during pregnancy is linked with a slightly increased risk of malformations in infants, according to a recent analysis of published studies.

In the analysis of 16 studies, infants exposed to fluoxetine during the first trimester had an 18% increased relative risk of major malformations and a 36% increased relative risk of cardiovascular malformations. There were no significant observations of other system-specific malformations in the nervous system, eye, urogenital system, digestive system, respiratory system, or musculoskeletal system.

The findings are published in the British Journal of Clinical Pharmacology.

Similar research was published at an earlier time in the British Journal of Clinical Pharmacology

Latest news & activity

 

The British Pharmacological Society’s recent position statement on medicines in pregnancy and breastfeeding has received strong national media…

Policy statement

The British Pharmacological Society (BPS) has published a new position statement highlighting the urgent need for clearer, evidence-based guidance on…

Editor's pick

The British Journal of Pharmacology (BJP) has published its mini-review of ‘Novel drugs approved by the EMA, the FDA and the MHRA in 2025’.

This is…